2010～2015年浙江省11家医院肺癌患者5-HT_3受体拮抗药应用分析  

Application Analysis of 5-HT_3 Receptor Antagonists Used for Lung Cancer in 11 Hospitals of Zhejiang from 2010 to 2015

作　　者：孙娇[1] 孔思思 郑小卫[1] 张轶雯[1] 方罗[1] 

机构地区：[1]浙江省肿瘤医院药剂科,杭州310022

出　　处：《药物流行病学杂志》2017年第6期417-420,共4页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:了解2010~2015年浙江省11家医院肺癌患者5-HT_3受体拮抗药的应用情况和趋势,促进其合理用药。方法:抽取2010~2015年浙江省11家医院肺癌患者的医嘱用药数据,对其用药金额、用药频度(DDDs)、限定日费用(DDC)进行回顾性分析。结果:2010~2015年,浙江省11家医院肺癌患者使用5-HT_3受体拮抗药的用药金额逐年上升,但在总金额中的占比呈下降趋势,而2015年5-HT_3受体拮抗药不论用药金额还是占总用药金额比例都有所升高。6年内使用金额比例排名首位的分别为托烷司琼(2010~2014年)和帕洛诺司琼(2015年)。5-HT_3受体拮抗药DDDs排名首位是托烷司琼(2010~2015年),DDC排名首位为帕洛诺司琼。结论:浙江省11家医院肺癌患者使用的5-HT_3受体拮抗药基本合理,安全有效、经济方便的5-HT_3受体拮抗药在临床使用中占优势。Objective： To investigate the utilization, characteristic and tendency of 5-HT3 receptor antagonists used by lung cancer patients and to provide reference resources. Methods ： Regard to consumption sum, DDDs, and DDC, the collected prescriptions data of 5-HT3 receptor antagonists used by lung cancer patients in 11 hospitals of Zhejiang during 2010-2015 were analyzed by the retrospective research method. Results：The consumption sum of 5-HT3 receptor antago- nists increased from 2010 to 2015. The top 5-HT3 receptor antagonists of the consumption sum were tropisetron （2010- 2014） and palonosetron （2015）, the top of DDDs were tropisetron, and palonosetron （2010-2015） took the first three drugs in DDC. Conclusion： The applications of 5-HT3 receptor antagonists used by lung cancer patients were basically rea- sonable in 11 hospitals of Zhejiang, and those drugs which were of rational, safe, effective and valid predominated in clini- cal application.

关 键 词：5-HT3受体拮抗药 肺癌 用药金额 用药频度 限定日费用 药物利用 

分 类 号：F407.7[经济管理—产业经济]